Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 3,054 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Colonic Cancer Clear all
Recruiting Phase 1 Interventional

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)
Interventions
MGC026 Dose Escalation, MGC026 Dose for Expansion
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Not applicable Interventional

Diet Education Program for Stage I-IV Colorectal Cancer Survivors

NCT04597151
View directory record Official record
Conditions
Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Dietary Intervention
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 23, 2026, 2:41 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT04430738
View directory record Official record
Conditions
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

NCT02961374
View directory record Official record
Conditions
Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
Interventions
Erlotinib, Erlotinib Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Scottsdale, Arizona • Ann Arbor, Michigan • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 23, 2026, 2:41 AM EDT
Terminated Phase 1 Interventional

One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy

NCT00358397
View directory record Official record
Conditions
Tumors
Interventions
Clostridium novyi-NT spores
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 23, 2026, 2:41 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Selenium for Prevention of Adenomatous Colorectal Polyps

NCT00078897
View directory record Official record
Conditions
Colorectal Cancer, Adenomatous Colorectal Polyps, Precancerous Condition
Interventions
Selenium
Drug
Lead sponsor
University of Arizona
Other
Eligibility
40 Years to 80 Years
Enrollment
1,621 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 23, 2026, 2:41 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Microbiome in Colorectal Cancer Onset and Progression

NCT05368688
View directory record Official record
Conditions
Colorectal Cancer, Tumor, CRC, GI Cancer, Gastrointestinal Cancer
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy

NCT04526886
View directory record Official record
Conditions
Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ampullary Cancer, Small Bowel Cancer, Appendix Cancer
Interventions
Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

NCT01478594
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Tivozanib, Bevacizumab, mFOLFOX6
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
27
States / cities
Gilbert, Arizona • Hot Springs, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

NCT01576666
View directory record Official record
Conditions
Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions
LDE225, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 23, 2026, 2:41 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380
View directory record Official record
Conditions
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Interventions
tucatinib, trastuzumab, fulvestrant
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
76
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00089362
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Gastric Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Melanoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Ovarian Epithelial Cancer, Recurrent Prostate Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Colon Cancer, Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage III Gastric Cancer, Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Melanoma, Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Ovarian Epithelial Cancer, Stage III Renal Cell Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Melanoma, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Ovarian Epithelial Cancer, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 2Phase 3 Interventional Results available

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

NCT03414983
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Nivolumab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating Strategies to Present Colon Cancer Screening Information

NCT02485561
View directory record Official record
Conditions
Colonic Neoplasms, Colorectal Neoplasms, Colonic Diseases, Gastrointestinal Neoplasms
Interventions
Health communication intervention, Education information
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 75 Years
Enrollment
486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

NCT00004879
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
panitumumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 23, 2026, 2:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Computer-Based Tailored or Standard Information for Colorectal Cancer Screening

NCT00955188
View directory record Official record
Conditions
Colorectal Cancer
Interventions
computer-assisted intervention, educational intervention, medical chart review
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
50 Years to 79 Years
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
3
States / cities
San Francisco, California • Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 4 Interventional

Assessment of Safety, Quality, and Acceptance of a Bowel Preparation Using a Food Kit With Laxatives

NCT07605897
View directory record Official record
Conditions
Bowel Preparation, Efficacy, Tolerability, Safety, Colon Cancer Screening, Bowel Preparation for Colonoscopy
Interventions
Use of a standardized meal content (food-kit) the day prior to colonoscopy, Polyethylene glycol 3350 - electrolyte solution (GoLYTELY)
Other · Drug
Lead sponsor
Joseph Spataro
Federal
Eligibility
18 Years to 69 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Preventive Health Behavior in Women

NCT00723996
View directory record Official record
Conditions
Colon Cancer
Interventions
Behavioral Study in Women
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 3 Interventional

Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors

NCT03781154
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Group Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 23, 2026, 2:41 AM EDT
Active, not recruiting Not applicable Interventional

Monopolar Current Cutting Knife vs Bipolar RFA Knife

NCT04919824
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
Endoscopic Submucosal Dissection, Endoscopic Mucosal Resection
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

NCT01239082
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colonoscopy, Fecal immunochemical test (FIT)
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
50,126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Engagement With Messages Regarding CRC Screening Among Adults Aged 45-49

NCT05281159
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms
Interventions
Risk Information, Risk Information + Action
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 49 Years
Enrollment
20,509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Colonoscope Insertion Trial Protocol

NCT01324882
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colonoscopy with Olympus Technically Improved Colonoscope, Control with standard colonoscope Olympus CF-H180
Device
Lead sponsor
UConn Health
Other
Eligibility
35 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 23, 2026, 2:41 AM EDT
Withdrawn No phase listed Observational

Metabiomics Colon Cancer Clinical Research Study

NCT02151123
View directory record Official record
Conditions
Colonic Neoplasms
Interventions
Not listed
Lead sponsor
Metabiomics Corp
Industry
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 23, 2026, 2:41 AM EDT